FDA Type 2a meeting scheduled for November 19, 2025, to review AEON's analytical development plan and initial data - - Positive biosimilarity data for ABP-450 confirming identical amino-acid sequencin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback